User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

Primary tabs

Bousser, M G Amarenco, P Chamorro, A Fisher, M Ford, I Peeters, André [UCL] Laloux, Patrice [UCL]

The PERFORM Study will explore the benefits and safety of terutroban in secondary cardiovascular prevention after a cerebral ischemic event.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2009
Language Anglais
Journal information "Cerebrovascular Diseases" - Vol. 27, no.5, p. 509-18 (2009)
Peer reviewed yes
Publisher S.Karger AG ((Switzerland) Basel)
issn 1015-9770
e-issn 1421-9786
Publication status Publié
Affiliations UCL - (MGD) Service de neurologie
UCL - MD/NOPS - Département de neurologie et de psychiatrie
MESH Subject Aged ; International Cooperation ; Ischemic Attack, Transient ; Male ; Middle Aged ; Naphthalenes ; Platelet Aggregation Inhibitors ; Propionates ; Receptors, Thromboxane ; Stroke ; Treatment Outcome ; Aged, 80 and over ; Aspirin ; Cardiovascular Diseases ; Dose-Response Relationship, Drug ; Double-Blind Method ; Endpoint Determination ; Female ; Humans
Links
Bibliographic reference Bousser, M G ; Amarenco, P ; Chamorro, A ; Fisher, M ; Ford, I ; et. al. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.. In: Cerebrovascular Diseases, Vol. 27, no.5, p. 509-18 (2009)
Permanent URL http://hdl.handle.net/2078.1/132703